[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO308107B1 - Ikke-solvatert krystallinsk forbindelse, farmasøytisk formulering inneholdende denne samt anvendelse av forbindelsen for fremstilling av et farmasøytisk middel - Google Patents

Ikke-solvatert krystallinsk forbindelse, farmasøytisk formulering inneholdende denne samt anvendelse av forbindelsen for fremstilling av et farmasøytisk middel

Info

Publication number
NO308107B1
NO308107B1 NO953657A NO953657A NO308107B1 NO 308107 B1 NO308107 B1 NO 308107B1 NO 953657 A NO953657 A NO 953657A NO 953657 A NO953657 A NO 953657A NO 308107 B1 NO308107 B1 NO 308107B1
Authority
NO
Norway
Prior art keywords
compound
preparation
formulation containing
pharmaceutical
unsolvated crystalline
Prior art date
Application number
NO953657A
Other languages
English (en)
Norwegian (no)
Other versions
NO953657D0 (no
NO953657L (no
Inventor
Elizabeth Smith Labell
Wayne Douglas Luke
Iii John Mcneill Mcgill
Randal Scot Miller
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO308107(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/308,325 external-priority patent/US5629425A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO953657D0 publication Critical patent/NO953657D0/no
Publication of NO953657L publication Critical patent/NO953657L/no
Publication of NO308107B1 publication Critical patent/NO308107B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO953657A 1994-09-19 1995-09-15 Ikke-solvatert krystallinsk forbindelse, farmasøytisk formulering inneholdende denne samt anvendelse av forbindelsen for fremstilling av et farmasøytisk middel NO308107B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/308,325 US5629425A (en) 1994-09-19 1994-09-19 Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US42791495A 1995-04-26 1995-04-26

Publications (3)

Publication Number Publication Date
NO953657D0 NO953657D0 (no) 1995-09-15
NO953657L NO953657L (no) 1996-03-20
NO308107B1 true NO308107B1 (no) 2000-07-24

Family

ID=26976194

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19953658A NO313996B1 (no) 1994-09-19 1995-09-15 Krystallinsk solvat av forbindelsen 6-hydroksy-2-(4- hydroksyfenyl)-3-[4-(2-piperidinoetoksy)benzoyl]benzo[b]tiofenhydroklorid, fremgangsmåtefor fremstilling av solvatet, og fremgangsmåte for fremstilling av en ikke-solvatisert utgaveav forbind
NO953657A NO308107B1 (no) 1994-09-19 1995-09-15 Ikke-solvatert krystallinsk forbindelse, farmasøytisk formulering inneholdende denne samt anvendelse av forbindelsen for fremstilling av et farmasøytisk middel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19953658A NO313996B1 (no) 1994-09-19 1995-09-15 Krystallinsk solvat av forbindelsen 6-hydroksy-2-(4- hydroksyfenyl)-3-[4-(2-piperidinoetoksy)benzoyl]benzo[b]tiofenhydroklorid, fremgangsmåtefor fremstilling av solvatet, og fremgangsmåte for fremstilling av en ikke-solvatisert utgaveav forbind

Country Status (51)

Country Link
US (4) US6399778B1 (zh)
JP (2) JPH08193081A (zh)
KR (2) KR100367376B1 (zh)
CN (2) CN1068324C (zh)
AP (1) AP754A (zh)
AT (2) AT407988B (zh)
AU (3) AU692907B2 (zh)
BE (2) BE1009625A3 (zh)
BG (1) BG62793B1 (zh)
BR (2) BR9504060A (zh)
CA (2) CA2158399C (zh)
CH (3) CH691478A5 (zh)
CO (2) CO4410190A1 (zh)
CZ (2) CZ290343B6 (zh)
DE (3) DE19549755B4 (zh)
DK (4) DK175903B1 (zh)
EE (1) EE03386B1 (zh)
EG (1) EG23763A (zh)
ES (2) ES2109882B1 (zh)
FI (2) FI112226B (zh)
FR (2) FR2732020B1 (zh)
GB (2) GB2293382B (zh)
GE (1) GEP19991821B (zh)
GR (2) GR1002709B (zh)
HK (1) HK1019009A1 (zh)
HR (2) HRP950483B1 (zh)
HU (2) HU227683B1 (zh)
IE (2) IE80883B1 (zh)
IL (3) IL125283A (zh)
IS (1) IS1788B (zh)
IT (2) IT1277601B1 (zh)
LU (2) LU88660A1 (zh)
LV (2) LV11178B (zh)
MY (1) MY116371A (zh)
NL (2) NL1001194C2 (zh)
NO (2) NO313996B1 (zh)
NZ (2) NZ280027A (zh)
OA (1) OA10406A (zh)
PE (2) PE32796A1 (zh)
PL (2) PL187686B1 (zh)
PT (2) PT101770B (zh)
RO (2) RO115259B1 (zh)
RS (2) RS49513B (zh)
SE (2) SE509265C2 (zh)
SI (2) SI9500293A (zh)
SK (1) SK283502B6 (zh)
TR (1) TR199501136A2 (zh)
TW (1) TW412534B (zh)
UA (2) UA42716C2 (zh)
UY (1) UY24040A1 (zh)
WO (1) WO1996009045A1 (zh)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
MEP18308A (en) 1996-03-26 2010-06-10 Lilly Co Eli Benzothiophenes, formulations containing same, and methods
RU2203060C2 (ru) 1996-10-30 2003-04-27 Эли Лилли Энд Компани Способ профилактики рака молочной железы
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
ES2246234T3 (es) 1999-05-04 2006-02-16 Strakan International Limited Glicosidos de androgenos y actividad androgenica de los mismos.
AU2002230409A1 (en) * 2000-11-27 2002-06-03 Eli Lilly And Company Process for preparing 3-aryl-benzo(b)thiophenes
CA2477088A1 (en) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2004029046A2 (en) * 2002-09-30 2004-04-08 A/S Gea Farmaceutisk Fabrik Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP5215666B2 (ja) 2004-09-29 2013-06-19 バイエル・ファルマ・アクチェンゲゼルシャフト Ｂａｙ４３−９００６トシレートの熱力学的に安定な形態
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN103951667A (zh) 2006-05-04 2014-07-30 勃林格殷格翰国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
KR20090082399A (ko) * 2006-10-17 2009-07-30 씨아이피엘에이 엘티디. 벤조티오펜 화합물의 결정형 및 그의 제조방법
US8258291B2 (en) * 2006-10-25 2012-09-04 Mamtek International Limited Process for the preparation of sucralose by the chlorination of sugar with triphosgene (BTC)
US20080103295A1 (en) * 2006-10-25 2008-05-01 David Losan Ho Process for the preparation of sucrose-6-ester by esterification in the presence of solid superacid catalyst
DE102007032451B4 (de) 2007-07-12 2010-09-30 Icfs Gmbh Verfahren zur Herstellung von aromatischen Ketonen
WO2009015004A1 (en) * 2007-07-20 2009-01-29 King Pharmaceuticals Research And Development, Inc. Crystals of (2-amino-4,5,6,7-tetrahydrobenzo[b]thien-3-yl)(4-chlorophenyl)methanone
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
WO2009080364A1 (en) * 2007-12-21 2009-07-02 Synthon B.V. Raloxifene composition
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20110088613A1 (en) * 2008-06-09 2011-04-21 Massimo Ferrari Process for controlling the growth of a raloxifene hydrochloride crystal
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
EP2448562B1 (en) 2009-07-02 2013-11-06 Synthon B.V. Raloxifene composition
EP2314581B1 (en) 2009-10-23 2012-07-25 Hexal AG A process for preparing benzo[b]thiophene derivatives
KR102328772B1 (ko) 2009-11-27 2021-11-19 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
IT1403083B1 (it) * 2010-10-25 2013-10-04 Fidia Farmaceutici Nuova forma polimorfa di raloxifene cloridrato
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
JP5876150B2 (ja) 2011-07-15 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キナゾリン、これらの調製及び医薬組成物中のこれらの使用
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
IN2013MU00665A (zh) 2013-03-05 2015-07-03 Cipla Ltd
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN104496963A (zh) * 2014-12-02 2015-04-08 千辉药业（安徽）有限责任公司 一种盐酸雷洛昔芬的制备方法
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869485A (en) * 1969-09-25 1975-03-04 Allied Chem Preparation of acid chlorides with phosgene in the presence of a catalyst
GB1456323A (en) * 1974-06-06 1976-11-24 Labaz Benzothiophenes process for preparing them and pharmaceutical compositions containing the same
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4358593A (en) 1981-04-03 1982-11-09 Eli Lilly And Company Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
IL65378A (en) * 1981-04-03 1986-02-28 Lilly Co Eli Process for preparing 3-(4-aminoethoxybenzoyl)benzo-(b)thiophenes
EP0062503A1 (en) * 1981-04-03 1982-10-13 Eli Lilly And Company Benzothiophene compounds and process for preparing them
ZA822247B (en) 1981-04-03 1983-11-30 Lilly Co Eli Benzothiophene compounds and process for preparing them
IL65379A0 (en) * 1981-04-03 1982-05-31 Lilly Co Eli Process for preparing acylated benzothiophenes
DE4117512A1 (de) 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5169860A (en) 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
DE69405491T2 (de) * 1993-06-24 1998-02-19 Lilly Co Eli Antiöstrogene 2-Phenyl-3-Aroylbenzothiophene als hypoglykämische Mittel
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5523416A (en) 1994-07-22 1996-06-04 Eli Lilly And Company Process for preparing 3-(4-aminoethoxy-benzoyl) benzo (B)-thiophenes
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO

Also Published As

Publication number Publication date
GEP19991821B (en) 1999-11-05
LV11177A (lv) 1996-04-20
SI9500293A (en) 1996-06-30
CO4410191A1 (es) 1997-01-09
GB2293602B (en) 1998-05-06
NO313996B1 (no) 2003-01-13
AU3718695A (en) 1996-04-09
CA2158399C (en) 2001-03-20
CH691594A5 (de) 2001-08-31
HRP950483B1 (en) 2003-02-28
CN1075069C (zh) 2001-11-21
IT1277601B1 (it) 1997-11-11
HK1019009A1 (en) 2000-01-14
HU225417B1 (en) 2006-11-28
BE1009626A3 (fr) 1997-06-03
NZ280028A (en) 1997-05-26
NL1001196C2 (nl) 1997-04-04
IE950721A1 (en) 1996-03-20
FI954402A (fi) 1996-03-20
NO953657D0 (no) 1995-09-15
BG62793B1 (bg) 2000-08-31
IL115315A0 (en) 1995-12-31
HUT75033A (en) 1997-03-28
HRP950482A2 (en) 1998-02-28
UA44240C2 (uk) 2002-02-15
SK23397A3 (en) 1997-08-06
LU88661A1 (fr) 1996-07-15
AT502957A1 (de) 2007-06-15
YU61495A (sh) 1998-05-15
AP754A (en) 1999-07-22
LV11177B (en) 1996-08-20
CN1068324C (zh) 2001-07-11
GR1002709B (el) 1997-06-04
ES2129293A1 (es) 1999-06-01
SE9503214D0 (sv) 1995-09-15
RO115260B1 (ro) 1999-12-30
JPH08176147A (ja) 1996-07-09
BR9504059A (pt) 1996-09-24
PL182450B1 (pl) 2002-01-31
GR1002697B (el) 1997-05-22
PL310518A1 (en) 1996-04-01
CN1127253A (zh) 1996-07-24
EE9700055A (et) 1997-08-15
CA2158400C (en) 2006-10-24
NZ280027A (en) 1997-05-26
SE9503214L (sv) 1996-03-20
PT101771B (pt) 1997-04-30
CZ292007B6 (cs) 2003-07-16
ITMI951936A1 (it) 1997-03-15
DK102795A (da) 1996-03-20
HUT74178A (en) 1996-11-28
CN1132205A (zh) 1996-10-02
BE1009625A3 (fr) 1997-06-03
IL115315A (en) 1999-09-22
DK175897B1 (da) 2005-05-30
SI9500292A (en) 1996-06-30
EG23763A (en) 2007-08-08
IS1788B (is) 2001-11-28
PL310517A1 (en) 1996-04-01
KR100367376B1 (ko) 2003-03-06
TR199501136A2 (tr) 1996-06-21
RS49513B (sr) 2006-10-27
DK2897A (da) 1997-01-09
SE520721C2 (sv) 2003-08-12
SE9503213L (sv) 1996-03-20
PE32796A1 (es) 1996-08-07
CA2158400A1 (en) 1996-03-20
AU3173195A (en) 1996-04-04
FR2732020A1 (fr) 1996-09-27
FI954402A0 (fi) 1995-09-18
NL1001196A1 (nl) 1996-03-19
DE19534744A1 (de) 1996-03-21
GB2293382A (en) 1996-03-27
ITMI951935A1 (it) 1997-03-15
KR100381346B1 (ko) 2004-04-13
TW412534B (en) 2000-11-21
DE19534745B4 (de) 2004-06-09
US5731327A (en) 1998-03-24
HU9502723D0 (en) 1995-11-28
NO953658L (no) 1996-03-20
IS4446A (is) 1997-03-18
PL187686B1 (pl) 2004-09-30
YU61395A (sh) 1998-09-18
DK175903B1 (da) 2005-06-06
GB2293602A (en) 1996-04-03
CZ240295A3 (en) 1996-04-17
ITMI951935A0 (it) 1995-09-15
JP2860071B2 (ja) 1999-02-24
JPH08193081A (ja) 1996-07-30
CH691478A5 (de) 2001-07-31
CZ290343B6 (cs) 2002-07-17
NO953658D0 (no) 1995-09-15
AU692907B2 (en) 1998-06-18
PT101770A (pt) 1996-04-30
EE03386B1 (et) 2001-04-16
PT101771A (pt) 1996-04-30
LV11178A (lv) 1996-04-20
UY24040A1 (es) 1996-03-07
SK283502B6 (sk) 2003-08-05
DE19549755B4 (de) 2005-05-04
HRP950482B1 (en) 2007-04-30
LV11178B (en) 1996-08-20
FR2732020B1 (fr) 1997-11-14
KR960010634A (ko) 1996-04-20
HU9502721D0 (en) 1995-11-28
GB9519028D0 (en) 1995-11-15
BR9504060A (pt) 1996-09-24
GB9519032D0 (en) 1995-11-15
FI121424B (fi) 2010-11-15
HU227683B1 (en) 2011-11-28
HRP950483A2 (en) 1997-10-31
NL1001194A1 (nl) 1996-03-19
DK175887B1 (da) 2005-05-23
ITMI951936A0 (it) 1995-09-15
UA42716C2 (uk) 2001-11-15
WO1996009045A1 (en) 1996-03-28
IT1277602B1 (it) 1997-11-11
US6472531B1 (en) 2002-10-29
AT407988B (de) 2001-07-25
ES2109882B1 (es) 1998-08-16
CZ240395A3 (en) 1996-04-17
RS49578B (sr) 2007-04-10
OA10406A (en) 2001-12-05
IL115314A (en) 2000-02-29
IL125283A (en) 2001-06-14
ATA154295A (de) 2000-12-15
BG101242A (en) 1998-03-31
KR960010637A (ko) 1996-04-20
CA2158399A1 (en) 1996-03-20
AU691955B2 (en) 1998-05-28
IE80883B1 (en) 1999-05-19
NO953657L (no) 1996-03-20
NL1001194C2 (nl) 1997-04-04
DK175886B1 (da) 2005-05-23
FI954403A0 (fi) 1995-09-18
IL115314A0 (en) 1996-05-14
FI954403A (fi) 1996-03-20
ES2129293B1 (es) 2000-01-16
FI112226B (fi) 2003-11-14
US6399778B1 (en) 2002-06-04
SE9503213D0 (sv) 1995-09-15
IE950722A1 (en) 1996-03-20
AU3173095A (en) 1996-04-04
AP9700938A0 (en) 1997-04-30
SE509265C2 (sv) 1998-12-21
GB2293382B (en) 1998-08-19
FR2724655A1 (fr) 1996-03-22
DK2797A (da) 1997-01-09
CO4410190A1 (es) 1997-01-09
ES2109882A1 (es) 1998-01-16
CH691125A5 (de) 2001-04-30
PT101770B (pt) 1997-04-30
LU88660A1 (fr) 1996-07-15
RO115259B1 (ro) 1999-12-30
US20020173645A1 (en) 2002-11-21
PE14796A1 (es) 1996-05-19
DK102895A (da) 1996-03-20
DE19534745A1 (de) 1996-04-04
MY116371A (en) 2004-01-31
FR2724655B1 (fr) 1997-11-14

Similar Documents

Publication Publication Date Title
NO308107B1 (no) Ikke-solvatert krystallinsk forbindelse, farmasøytisk formulering inneholdende denne samt anvendelse av forbindelsen for fremstilling av et farmasøytisk middel
AR027162A1 (es) Compuestos de 2-fenil-3-fenoxilo-feniltio-benzotiofeno, sales farmaceuticamente aceptables de los mismos y composiciones farmaceuticas que los contienen
NO306725B1 (no) Ny krystallmodifikasjon av CDCH, fremgangsmate for fremstilling derav og farmasoytiske preparater inneholdende denne samt anvendelse av forbindelsen for fremstilling av legemidler
NO304468B1 (no) 6-leddede nitrogenholdige heteroaryl-oksazolidinoner, anvendelse av disse samt legemiddel inneholdende forbindelsen
HUP9902092A3 (en) Metalloproteinase inhibitor benzenesulfonamide derivatives, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
NO942864L (no) Benzokondenserte 5-ringheterocykler, fremgangsmåte for fremstilling derav, deres anvendelse som medikament, deres anvendelse som diagnostikum samt medikament inneholdene disse
HUP9901159A3 (en) Substituted benzylaminopiperidine derivatives and use thereof, pharmaceutical compositions containing these compounds
NO903925D0 (no) Fremgangsmaate for fremstilling av 3-(1-substituert-4-piperazinyl)-1h-indazoler samt anvendelse som legemidler.
AU2109195A (en) Two-component device for the administration of drugs
NO944526D0 (no) Medisinsk aerosolformulering
NO944700D0 (no) Nye tienotiazinderivater, fremgangsmåte for fremstilling derav samt farmasöytiske preparater inneholdende forbindelsene
NO20040145L (no) Anvendelse av benzensulfonamidderivater for fremstilling av et medikament
NO305903B1 (no) Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
DE69528769D1 (de) Aerosolformulierung für arzneimittel enthaltend polyglycolisierte glyzeride
NO964639L (no) Substituerte sulfonimidamider, fremgangsmåte for fremstilling derav, deres anvendelse som medikament eller diagnostikum samt medikament inneholdende forbindelsen
IL133097A0 (en) Aroyl-piperazine derivatives pharmaceutical compositions containing the same and the use thereof
NO305906B1 (no) Adhesjonsreseptorantagonister, farmasöytiske preparater som inneholder slike forbindelser, samt anvendelse av forbindelsene til fremstilling av legemidler
BR9610821A (pt) Derivado de aminoácido uso de um composto e medicamento contendo o mesmo
NO953367L (no) Anvendelse av substituerte 4-fenyl-6-amino-nikotinsyre-derivater som legemidler
IL134536A0 (en) Compounds possessing neuronal activity and pharmaceutical compositions containing the same
NO20006646D0 (no) Aminosyrederivater og legemidler inneholdende de samme som aktiv bestanddel
NO306347B1 (no) Eleutherobin og analoger av denne, anvendelse av forbindelsen samt farmasöytisk preparat inneholdende denne
HUP0100853A3 (en) Nitrate salt of anti-ulcer medicine and pharmaceutical compositions containing the same compounds
NO306113B1 (no) Adhesjonsreseptorantagonister, farmasöytiske preparater som inneholder slike forbindelser, samt anvendelse av forbindelsene til fremstilling av legemidler
HUP9901873A3 (en) Benzisoxazole and benzisoxazolidinone derivatives, preparation of the latter, herbicide compositions containing these compounds and use thereof

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees